NASDAQ · SRZN
Surrozen, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for SRZN: Nov 6, 2026
Surrozen, Inc. Common Stock is estimated to report earnings on 11/06/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 2 analysts' forecasts, the consensus EPS forecast for the quarter is $-1.32. The reported EPS for the same quarter last year was $-3.61.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-1.32 | $-1.30 | $-1.33 | 2 |
| Dec 2026 | $-1.07 | $-0.83 | $-1.31 | 2 |
| Mar 2027 | $-0.87 | $-0.87 | $-0.87 | 1 |
| Jun 2027 | $-0.90 | $-0.90 | $-0.90 | 1 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
RTTNews · MarketBeat · Fintel · Zacks- RTTNews · Oct 2, 8:51 AM EDTSurrozen's SZN-8141 IND Cleared By FDA For Diabetic Macular Edema(RTTNews) – Friday, Surrozen (SRZN) said that the FDA has cleared its Investigational New Drug (IND) application for SZN-8141, enabling clinical development of the drug candidate for diabetic macular edema.
- RTTNews · Sep 8, 11:47 AM EDTSurrozen Submits IND Application For SZN-8141 In Diabetic Macular Edema(RTTNews) – Surrozen, Inc. (SRZN) announced the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for SZN-8141, a bifunctional Wnt agonist and vascular endothelial growth factor (VEGF) antagonist antibody being developed fo
- MarketBeat · Jul 22, 4:02 PM EDTSurrozen Highlights Wnt Retina Pipeline, SZN-8141 IND Timeline at H.C. WainwrightSurrozen (NASDAQ:SRZN) Chief Executive Officer Craig Parker outlined the company’s rationale for developing Wnt-targeting retinal disease therapies during H.C. Wainwright’s 6th Annual Ophthalmology Investor Conference, emphasizing the company’s focus on Frizzled-4 signaling, anti
- Fintel · May 14, 3:41 PM EDTSurrozen (SRZN) Price Target Increased by 10.11% to 43.52The average one-year price target for Surrozen (NasdaqCM:SRZN) has been revised to $43.52 / share. This is an increase of 10.11% from the prior estimate of $39.52 dated April 25, 2026. The price target is an average of many targets provided by analysts. The la
- Fintel · Apr 21, 8:04 PM EDTTD Cowen Initiates Coverage of Surrozen (SRZN) with Buy RecommendationFintel reports that on April 21, 2026, TD Cowen initiated coverage of Surrozen (NasdaqCM:SRZN) with a Buy recommendation. Analyst Price Forecast Suggests 27.29% Upside
- Zacks · Apr 15, 7:06 AM EDTAvita Medical (RCEL) Soars 14.1%: Is Further Upside Left in the Stock?Avita Medical (RCEL) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
- Zacks · Apr 14, 9:28 AM EDTSurrozen (SRZN) Surges 5.9%: Is This an Indication of Further Gains?Surrozen (SRZN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
- Fintel · Feb 19, 9:04 AM ESTCantor Fitzgerald Initiates Coverage of Surrozen (SRZN) with Overweight RecommendationFintel reports that on February 19, 2026, Cantor Fitzgerald initiated coverage of Surrozen (NasdaqCM:SRZN) with a Overweight recommendation. Analyst Price Forecast Suggests 70.75% Upside
- Fintel · Feb 4, 1:44 PM ESTSurrozen (SRZN) Price Target Increased by 13.51% to 42.84The average one-year price target for Surrozen (NasdaqCM:SRZN) has been revised to $42.84 / share. This is an increase of 13.51% from the prior estimate of $37.74 dated January 11, 2026. The price target is an average of many targets provided by analysts. The
- The Motley Fool · Aug 8, 5:21 PM EDTSurrozen Reports Q2 Profit on GainsSurrozen reported GAAP EPS of $2.55 for Q2 2025, exceeding expectations by $3.66 per share (GAAP) due to significant one-time and non-cash gains.
- Zacks · May 16, 9:35 AM EDTDown -29.72% in 4 Weeks, Here's Why Surrozen (SRZN) Looks Ripe for a TurnaroundSurrozen (SRZN) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
- Quiver Quantitative · May 9, 4:12 PM EDTSurrozen, Inc. Reports First Quarter 2025 Financial Results and Business Update Focused on Ophthalmology PipelineSurrozen reported Q1 2025 financial results and announced a strategic pivot to focus on therapies for severe eye diseases.
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Surrozen, Inc. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.